Rebecca B. Perkins, N. Wentzensen, Richard S. Guido, Mark Schiffman
{"title":"宫颈癌筛查：综述","authors":"Rebecca B. Perkins, N. Wentzensen, Richard S. Guido, Mark Schiffman","doi":"10.1097/01.ogx.0001004660.29812.17","DOIUrl":null,"url":null,"abstract":"(Abstracted from JAMA 2023;330(6):547–558)\n More than 90% of cervical cancer is caused by persistent infections with carcinogenic human papillomavirus (HPV), leading to precancer and then to cervical cancer. Approximately 100,000 people are treated for cervical precancer, 14,000 people are diagnosed with cervical cancer, and more than 4000 die of cervical cancer in the United States each year.","PeriodicalId":144618,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"610 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cervical Cancer Screening: A Review\",\"authors\":\"Rebecca B. Perkins, N. Wentzensen, Richard S. Guido, Mark Schiffman\",\"doi\":\"10.1097/01.ogx.0001004660.29812.17\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(Abstracted from JAMA 2023;330(6):547–558)\\n More than 90% of cervical cancer is caused by persistent infections with carcinogenic human papillomavirus (HPV), leading to precancer and then to cervical cancer. Approximately 100,000 people are treated for cervical precancer, 14,000 people are diagnosed with cervical cancer, and more than 4000 die of cervical cancer in the United States each year.\",\"PeriodicalId\":144618,\"journal\":{\"name\":\"Obstetrical & Gynecological Survey\",\"volume\":\"610 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrical & Gynecological Survey\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.ogx.0001004660.29812.17\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.ogx.0001004660.29812.17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
(Abstracted from JAMA 2023;330(6):547–558)
More than 90% of cervical cancer is caused by persistent infections with carcinogenic human papillomavirus (HPV), leading to precancer and then to cervical cancer. Approximately 100,000 people are treated for cervical precancer, 14,000 people are diagnosed with cervical cancer, and more than 4000 die of cervical cancer in the United States each year.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
